Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Agios Pharmaceuticals (AGIO) EBT: 2012-2025

Historic EBT for Agios Pharmaceuticals (AGIO) over the last 14 years, with Sep 2025 value amounting to -$103.4 million.

  • Agios Pharmaceuticals' EBT fell 110.33% to -$103.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$411.9 million, marking a year-over-year decrease of 156.88%. This contributed to the annual value of $718.0 million for FY2024, which is 303.92% up from last year.
  • Per Agios Pharmaceuticals' latest filing, its EBT stood at -$103.4 million for Q3 2025, which was up 8.09% from -$112.5 million recorded in Q2 2025.
  • Agios Pharmaceuticals' 5-year EBT high stood at $1.0 billion for Q3 2024, and its period low was -$112.5 million during Q2 2025.
  • Moreover, its 3-year median value for EBT was -$91.3 million (2023), whereas its average is $4.8 million.
  • In the last 5 years, Agios Pharmaceuticals' EBT surged by 1,196.14% in 2024 and then slumped by 110.33% in 2025.
  • Quarterly analysis of 5 years shows Agios Pharmaceuticals' EBT stood at -$98.6 million in 2021, then climbed by 5.98% to -$92.7 million in 2022, then fell by 3.51% to -$95.9 million in 2023, then fell by 9.86% to -$105.4 million in 2024, then plummeted by 110.33% to -$103.4 million in 2025.
  • Its last three reported values are -$103.4 million in Q3 2025, -$112.5 million for Q2 2025, and -$90.5 million during Q1 2025.